Piceatannol, a SYK selective inhibitor, exhibited anticancer abilities by inhibiting proliferation and inducing apoptosis in many different tumors, including leukemia, lymphoma, melanoma, prostate and colon cancers [21, 32–35]. Here, SYK is linked to malignant colon neoplasm.